Literature DB >> 10200527

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.

S Dan1, M Naito, T Tsuruo.   

Abstract

The BCR - ABL tyrosine kinase has been implicated as the cause of Philadelphia chromosome (Ph1)-positive leukemias. We report herein that CGP 57148, a selective inhibitor of the ABL tyrosine kinase, caused apoptosis specifically in bcr - abl-positive chronic myelogenous leukemia (CML) cells, K562 and KYO-1. Upon treatment with CGP 57148, CRKL, a specific substrate for BCR - ABL that propagates signals via phosphatidylinositol-3' kinase (PI3K), was dephosphorylated, indicating inhibition of BCR - ABL tyrosine kinase at the cellular level. Likewise, MAPK/ERK, a downstream mediator of Ras, was also dephosphorylated. Caspase activation and cleavage of retinoblastoma protein (pRB) accompanied the development of CGP 57148-induced apoptosis. Inhibition of caspase suppressed apoptosis and the cleavage of pRB, and in turn arrested cells in the G1 phase. These results indicate that CGP 57148 shows apoptogenic and anti-proliferative effects on bcr - abl-positive cells by blocking BCR - ABL-initiated signaling pathways.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10200527     DOI: 10.1038/sj.cdd.4400400

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  18 in total

1.  Imatinib spells BAD news for Bcr/abl-positive leukemias.

Authors:  Scott H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-26       Impact factor: 11.205

2.  Reversal of experimental pulmonary hypertension by PDGF inhibition.

Authors:  Ralph Theo Schermuly; Eva Dony; Hossein Ardeschir Ghofrani; Soni Pullamsetti; Rajkumar Savai; Markus Roth; Akylbek Sydykov; Ying Ju Lai; Norbert Weissmann; Werner Seeger; Friedrich Grimminger
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

3.  Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.

Authors:  Alicia Cole; Zezhou Wang; Etienne Coyaud; Veronique Voisin; Marcela Gronda; Yulia Jitkova; Rachel Mattson; Rose Hurren; Sonja Babovic; Neil Maclean; Ian Restall; Xiaoming Wang; Danny V Jeyaraju; Mahadeo A Sukhai; Swayam Prabha; Shaheena Bashir; Ashwin Ramakrishnan; Elisa Leung; Yi Hua Qia; Nianxian Zhang; Kevin R Combes; Troy Ketela; Fengshu Lin; Walid A Houry; Ahmed Aman; Rima Al-Awar; Wei Zheng; Erno Wienholds; Chang Jiang Xu; John Dick; Jean C Y Wang; Jason Moffat; Mark D Minden; Connie J Eaves; Gary D Bader; Zhenyue Hao; Steven M Kornblau; Brian Raught; Aaron D Schimmer
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

Review 4.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

5.  ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Authors:  Clara I Aceves-Luquero; Anupriya Agarwal; Juan L Callejas-Valera; Laura Arias-González; Azucena Esparís-Ogando; Luis del Peso Ovalle; Itxaso Bellón-Echeverria; Miguel A de la Cruz-Morcillo; Eva M Galán Moya; Inmaculada Moreno Gimeno; Juan C Gómez; Michael W Deininger; Atanasio Pandiella; Ricardo Sánchez Prieto
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

6.  Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

Authors:  Cindy S Hwang; Victor G Prieto; Abdul H Diwan; Gregory Lizee; Julie A Ellerhorst; Suhendan Ekmekcioglu; Ping Liu; Omar Eton; Sandra A Kinney; Elizabeth A Grimm; Patrick Hwu; Kevin B Kim
Journal:  Melanoma Res       Date:  2008-08       Impact factor: 3.599

Review 7.  Genomic and proteomic biomarkers for cancer: a multitude of opportunities.

Authors:  Michael A Tainsky
Journal:  Biochim Biophys Acta       Date:  2009-05-04

Review 8.  Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Authors:  Ayalew Tefferi; Animesh Pardanani
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

Review 9.  Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Authors:  Chikashi Yoshida; Junia V Melo
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

10.  Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death.

Authors:  Guillaume Robert; Issam Ben Sahra; Alexandre Puissant; Pascal Colosetti; Nathalie Belhacene; Pierre Gounon; Paul Hofman; Fréderic Bost; Jill-Patrice Cassuto; Patrick Auberger
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.